NOVO.B.DK

240.85

+2.71%↑

GMAB.DK

1,789.5

+2.4%↑

HLUNB.DK

39.68

+0.25%↑

ZEAL.DK

294.9

+6.85%↑

AMBUB.DK

65.7

+1.47%↑

NOVO.B.DK

240.85

+2.71%↑

GMAB.DK

1,789.5

+2.4%↑

HLUNB.DK

39.68

+0.25%↑

ZEAL.DK

294.9

+6.85%↑

AMBUB.DK

65.7

+1.47%↑

NOVO.B.DK

240.85

+2.71%↑

GMAB.DK

1,789.5

+2.4%↑

HLUNB.DK

39.68

+0.25%↑

ZEAL.DK

294.9

+6.85%↑

AMBUB.DK

65.7

+1.47%↑

NOVO.B.DK

240.85

+2.71%↑

GMAB.DK

1,789.5

+2.4%↑

HLUNB.DK

39.68

+0.25%↑

ZEAL.DK

294.9

+6.85%↑

AMBUB.DK

65.7

+1.47%↑

NOVO.B.DK

240.85

+2.71%↑

GMAB.DK

1,789.5

+2.4%↑

HLUNB.DK

39.68

+0.25%↑

ZEAL.DK

294.9

+6.85%↑

AMBUB.DK

65.7

+1.47%↑

Search

Coloplast A-S (Class B)

Fechado

435 1.83

Visão Geral

Variação de preço das ações

24h

Atual

Mín

427.2

Máximo

441.5

Indicadores-chave

By Trading Economics

Rendimento

522M

1.4B

Vendas

83M

7B

P/E

Médio do Setor

24.41

66.418

EPS

6.32

Rendimento de Dividendos

5.19

Margem de lucro

19.835

Funcionários

16,983

EBITDA

309M

2.3B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+11.86% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

5.19%

2.36%

Próximos Ganhos

12 de mai. de 2026

Próxima data de dividendos

20 de mai. de 2026

Próxima data de ex-dividendo

18 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-21B

97B

Abertura anterior

433.17

Fecho anterior

435

Coloplast A-S (Class B) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de abr. de 2026, 20:44 UTC

Ganhos

Costco Reports 11% Growth in March Sales

8 de abr. de 2026, 23:51 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de abr. de 2026, 23:51 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8 de abr. de 2026, 23:36 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Lower on Likely Technical Correction -- Market Talk

8 de abr. de 2026, 22:56 UTC

Conversa de Mercado

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8 de abr. de 2026, 22:45 UTC

Conversa de Mercado

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8 de abr. de 2026, 22:17 UTC

Conversa de Mercado

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8 de abr. de 2026, 21:52 UTC

Notícias Principais

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8 de abr. de 2026, 21:24 UTC

Ganhos

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8 de abr. de 2026, 21:01 UTC

Notícias Principais

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

8 de abr. de 2026, 20:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8 de abr. de 2026, 20:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8 de abr. de 2026, 20:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8 de abr. de 2026, 20:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8 de abr. de 2026, 20:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8 de abr. de 2026, 20:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle Responds to TRC Cap Mini-Tender Offer

8 de abr. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de abr. de 2026, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8 de abr. de 2026, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8 de abr. de 2026, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8 de abr. de 2026, 19:44 UTC

Ganhos

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8 de abr. de 2026, 19:16 UTC

Conversa de Mercado

Hogs Follow Cutout Prices Lower -- Market Talk

8 de abr. de 2026, 19:02 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

8 de abr. de 2026, 19:02 UTC

Conversa de Mercado

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8 de abr. de 2026, 18:58 UTC

Conversa de Mercado

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8 de abr. de 2026, 18:51 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de abr. de 2026, 18:51 UTC

Conversa de Mercado

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8 de abr. de 2026, 18:14 UTC

Notícias Principais

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8 de abr. de 2026, 18:05 UTC

Notícias Principais

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Comparação entre Pares

Variação de preço

Coloplast A-S (Class B) Previsão

Preço-alvo

By TipRanks

11.86% parte superior

Previsão para 12 meses

Média 901.38 DKK  11.86%

Máximo 1,056 DKK

Mínimo 720 DKK

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Coloplast A-S (Class B) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

8 ratings

2

Comprar

4

Manter

2

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat